Holen Sie sich die Stockscreener-App
59.51
7.87%
4.305
Schlusskurs vom Vortag:
$55.20
Offen:
$54.87
24-Stunden-Volumen:
2.19M
Relative Volume:
1.26
Marktkapitalisierung:
$5.71B
Einnahmen:
$38.34M
Nettoeinkommen (Verlust:
$-488.30M
KGV:
-10.66
EPS:
-5.5801
Netto-Cashflow:
$-303.14M
1W Leistung:
+8.98%
1M Leistung:
+8.96%
6M Leistung:
+8.50%
1J Leistung:
+34.11%
1-Tages-Spanne:
$53.75
$60.50
1-Wochen-Bereich:
$52.02
$60.50
52-Wochen-Spanne:
$30.04
$78.48
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Firmenname
Crispr Therapeutics Ag
Sektor
Branche
Telefon
(617) 315-4600
Adresse
BAARERSTRASSE 14, ZUG
Compare CRSP vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
59.51 | 5.30B | 38.34M | -488.30M | -303.14M | -5.5801 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.64 | 122.71B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
765.66 | 82.91B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
765.78 | 50.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.60 | 43.42B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
318.75 | 38.98B | 4.98B | 69.60M | 525.67M | 0.5198 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-18 | Eingeleitet | JP Morgan | Overweight |
| 2025-02-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-02-12 | Hochstufung | TD Cowen | Sell → Hold |
| 2025-02-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-06 | Bestätigt | Needham | Buy |
| 2024-08-02 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-06-28 | Fortgesetzt | Guggenheim | Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-11 | Herabstufung | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Eingeleitet | Mizuho | Buy |
| 2023-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-04-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-03-17 | Eingeleitet | Bryan Garnier | Buy |
| 2023-03-07 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-08-09 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-04-21 | Hochstufung | Jefferies | Hold → Buy |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2020-12-10 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-10 | Bestätigt | Needham | Buy |
| 2020-12-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Eingeleitet | BofA Securities | Buy |
| 2020-07-28 | Bestätigt | Needham | Buy |
| 2020-07-14 | Eingeleitet | SunTrust | Buy |
| 2020-06-15 | Bestätigt | Canaccord Genuity | Buy |
| 2020-03-05 | Eingeleitet | Stifel | Hold |
| 2020-02-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Eingeleitet | Jefferies | Buy |
| 2019-07-26 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-06-10 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-14 | Eingeleitet | William Blair | Mkt Perform |
| 2019-01-28 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-22 | Herabstufung | Citigroup | Neutral → Sell |
Alle ansehen
Crispr Therapeutics Ag Aktie (CRSP) Neueste Nachrichten
CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Should You Buy Shares of CRISPR Therapeutics in February? - aol.com
CRISPR Therapeutics AG (CRSP) Stock Analysis: Unveiling A 57% Potential Upside - DirectorsTalk Interviews
CRISPR Therapeutics AG Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Versant Venture Management LLC Decreases Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat
FDA's New Framework Could Benefit CRISPR Therapeutics (CRSP) - GuruFocus
(CRSP) Movement as an Input in Quant Signal Sets - Stock Traders Daily
CRISPR Therapeutics gains after earnings as pipeline hope grows - MSN
Rare disease pharmas could benefit from FDA guidance to accelerate development - Seeking Alpha
Volume Report: Will CRISPR Therapeutics AG benefit from sector rotation2025 Technical Overview & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
O Neil Global Advisors Inc. Acquires Shares of 168,715 CRISPR Therapeutics AG $CRSP - MarketBeat
How FDA RMAT Status For Zugo-cel Amid Wider Losses At CRISPR Therapeutics (CRSP) Has Changed Its Investment Story - simplywall.st
Vestmark Advisory Solutions Inc. Has $15.49 Million Stake in CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) General Counsel Sells $111,048.96 in Stock - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) CEO Sells $366,324.86 in Stock - MarketBeat
Is CRISPR Therapeutics Stock Going to $0, or Will the Hype Pay Off? - The Motley Fool
First Week of October 16th Options Trading For CRISPR Therapeutics (CRSP) - Nasdaq
CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows - Investing.com
The Gene‑Therapy Breakthrough Story You'll Be Mad You Ignored at These Prices - The Motley Fool
What’s next for CRISPR Therapeutics AG stockJuly 2025 Setups & Verified Entry Point Detection - mfd.ru
2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street - AOL.com
CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows - sharewise.com
Casgevy Rollout And Pipeline Progress Reshape CRISPR Therapeutics Investment Case - Yahoo Finance
Breakout Move: Will CRISPR Therapeutics AG benefit from sector rotationJuly 2025 Selloffs & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
CRISPR Therapeutics touts zugo-cel CAR-T gains, eyes autoimmune expansion at Citi oncology summit - MarketBeat
Casgevy Adoption And Pipeline Progress Reshape CRISPR Therapeutics Investment Story - Sahm
Crispr Therapeutics: Very High Risk, But Even Higher Potential Reward (NASDAQ:CRSP) - Seeking Alpha
Is CRISPR Therapeutics (CRSP) Turning CASGEVY Momentum Into a Broader Gene-Editing Platform Edge? - Sahm
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Galapagos (GLPG) and West Pharmaceutical Services (WST) - The Globe and Mail
Vertex: The Quiet Biotech Compounder I'd Happily Hold Through Any Market Crash - AOL.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Crispr Therapeutics AG (CRSP), Moderna (MRNA) and Disc Medicine (IRON) - The Globe and Mail
Crispr: Emphasis Shifts To Cardiovascular Pipeline Amid Slow Casgevy Launch (NASDAQ:CRSP) - Seeking Alpha
Crispr Therapeutics Q4: The Elite Time To Buy Is In 2027 (NASDAQ:CRSP) - Seeking Alpha
CRISPR Therapeutics AG (CRSP) is attracting investor attention: Here is what you should know - MSN
CRISPR Therapeutics (CRSP) Gets Analyst Boost with Price Target Increase | CRSP Stock News - GuruFocus
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Citigroup maintains CRSP (CRISPR Therapeutics AG) at Buy Feb 2026 - Meyka
CRISPR Therapeutics: Casgevy Outperformance and 2026 Pipeline Catalysts Drive Raised $80 Target and Buy, High Risk Rating - TipRanks
Assessing CRISPR Therapeutics (CRSP) Valuation After Recent Short Term Share Price Momentum - Sahm
CRISPR Therapeutics (NASDAQ:CRSP) Price Target Raised to $82.00 - Defense World
What is Brookline Cap M's Estimate for CRSP Q1 Earnings? - MarketBeat
Crispr Therapeutics Stock Target Raised Amidst Positive Momentum - StocksToTrade
Crispr Therapeutics Shares Surge as Analysts Increase Price Targets - timothysykes.com
Crispr Therapeutics’ Price Target Uplift Sparks Investor Interest - StocksToTrade
Crispr Therapeutics’ Stock Soars as Price Targets Rise - timothysykes.com
Is CRISPR Therapeutics AG part of any major indexWeekly Stock Report & Technical Buy Zone Confirmations - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Organon (OGN) - The Globe and Mail
Is CRISPR Therapeutics' (CRSP) Casgevy Momentum Enough to Offset Steep 2025 Revenue Declines? - Yahoo Finance
Published on: 2026-02-15 01:50:52 - mfd.ru
Will CRISPR Therapeutics AG benefit from current market trendsJuly 2025 Recap & Fast Moving Market Watchlists - mfd.ru
Analysts Conflicted on These Healthcare Names: Crispr Therapeutics AG (CRSP) and Bruker (BRKR) - The Globe and Mail
Finanzdaten der Crispr Therapeutics Ag-Aktie (CRSP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.66%
0.99%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):